



PerkinElmer Expands Presence in Asia, Opens New Center of Excellence in Singapore

SINGAPORE, Mar 01, 2009 (BUSINESS WIRE) --As part of its expanding commitment to helping advance drug discovery and life sciences research in Asia, PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, announced the inauguration of a new Center of Excellence (COE) in Singapore today, at a special event at the world-renowned A*STAR Biopolis research complex.

The Center of Excellence is the second Singapore-based facility of its kind opened by PerkinElmer in the past year. The Center will serve as a training and knowledge sharing facility for life sciences researchers located throughout the Pacific Rim. Operated by PerkinElmer's Bio-discovery business unit, the Center will provide advanced solutions in the areas of automation and detection, cellular imaging and analysis, and drug discovery and research reagents.

"PerkinElmer's decision to open an additional Center of Excellence in Singapore within a year underscores the Company's commitment to both environmental and human health and becoming an even more significant partner in Singapore's growing life sciences community," said Daniel Marshak, PhD, chief scientific officer and president of Greater China, PerkinElmer. "The new Center is also a testament to the compelling advantages of local and regional expertise. As we continue to expand into cellular sciences, we greatly anticipate working closely with both our regional and global customers through the new Center."

Richard Eglén, PhD, president, Bio-discovery, PerkinElmer, said, "PerkinElmer recognizes the importance of technical support and training to ensure that our customers benefit fully from our expertise in imaging and detection as well as our reagent biology and chemistry. We offer an optimal combination of life science research technologies, in addition to proven local expertise in all cellular science technologies." He added, "PerkinElmer looks forward to providing industry leading laboratory instruments, consumables, services and customer service to advance solutions for human health in Asia, and worldwide."

The newest Singapore COE is well equipped with PerkinElmer instruments, software and reagents for biotech, pharmaceutical and academic customers that enable scientific workshops, demonstrations and customer support and training. It also provides classroom courses with topics covering techniques for assay development and training of instrumentation and related analysis software.

PerkinElmer's first Singapore based Center of Excellence was opened in March 2008. This application center is dedicated to the critical issues surrounding environmental health. The first Center supports a wide range of detection instrumentation and applications for environmental, food, materials and oil industries, as well as for expanding PerkinElmer's EcoAnalytix™ revolutionary problem-solving initiative that addresses the global imperatives of food and consumer product safety, water quality and sustainable energy development

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately \$2 billion in 2008, has 8,400 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) fluctuations in the global economic and political environments; (4) markets into which we sell our products decline or do not grow as anticipated; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability

to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) our ability to produce an adequate quantity of products to meet our customers' demands; (12) the manufacture and sale of products may expose us to product liability claims; (13) our failure to maintain compliance with applicable government regulations; (14) regulatory changes; (15) our failure to comply with health care industry regulations; (16) economic, political and other risks associated with foreign operations; (17) our ability to retain key personnel; (18) restrictions in our credit agreements; (19) our ability to realize the full value of our intangible assets; (20) significant fluctuations in our stock price; and (21) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

SOURCE: PerkinElmer, Inc.

PerkinElmer, Inc.
Mario R. Fante
(781) 663-5602
mario.fante@perkinelmer.com

Copyright Business Wire 2009